STRM.BIO, a biotechnology company pioneering non-viral delivery technologies for in vivo cell and gene therapy, announced $8 million in Series Seed 2 financing. The financing provided by Recordati was supported by continued participation by existing investors Boehringer Ingelheim Ventures and Delos Capital, as well as new funding from Blue Bay Capital Fund. The Series Seed 2 round remains open, with the intent to close this round by Q1 2026.